A multicenter research team will investigate differences in genetics, epigenetics and cell biology between males and females, with the goal of more-personalized therapy approaches for glioblastoma.
Blocking a signaling pathway associated with the WISP1 protein may help slow glioblastoma development by disrupting maintenance of glioma stem cells and tumor-supportive macrophages.
Neuro-oncologist Manmeet Ahluwalia, MD, surveys the glioblastoma research landscape from bench studies to testing of targeted therapies, immunotherapies and more.
We profile four ongoing Cleveland Clinic-led clinical studies that are evaluating mechanistically diverse strategies to extend survival in patients with this formidable malignancy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An early human study suggests immunotherapy for glioblastoma may require targeting the immune suppressive effects of MDSCs along with immune activation tactics to overcome tumor-induced immunosuppression.
Differentiating true glioblastoma progression from pseudoprogression is a vexing challenge with big implications for management. New research reveals the promise of taking an algorithmic approach to MRI evaluation.
A new paradigm for glioma stem cell regulation may emerge from the discovery of a signaling loop that shows potential as a druggable target in glioblastoma.
Researchers seek to reduce tumor growth by inhibiting activity of immunosuppressive cells called myeloid-derived suppressor cells. The goal: new therapies that overcome glioblastoma’s therapeutic resistance.
Two studies of temozolomide therapy underscore the detrimental effects of immunosuppression in the setting of glioblastoma and the need to find new, immune system-enhancing therapies.
Emerging sex differences in multiple aspects of this lethal brain cancer likely help explain the disease’s more favorable incidence and prognosis in females. And they may point to new targeted therapies.